bioAffinity Technologies, Inc. (BIAF)
6.055
-0.09
(-1.46%)
USD |
NASDAQ |
Oct 02, 16:00
6.06
0.00 (0.00%)
After-Hours: 20:00
bioAffinity Technologies Gross Profit Margin (Quarterly) : 23.91% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.91% |
| March 31, 2026 | 22.82% |
| December 31, 2025 | 35.72% |
| September 30, 2025 | 27.00% |
| June 30, 2025 | 11.00% |
| March 31, 2025 | 17.86% |
| December 31, 2024 | 22.28% |
| September 30, 2024 | 32.29% |
| June 30, 2024 | 34.99% |
| Date | Value |
|---|---|
| March 31, 2024 | 28.40% |
| December 31, 2023 | 18.06% |
| September 30, 2023 | 55.68% |
| June 30, 2023 | -15.23% |
| March 31, 2023 | -2.32K% |
| December 31, 2022 | -226.1% |
| September 30, 2022 | 16.67% |
| June 30, 2022 | 7.69% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Veracyte, Inc. | 71.93% |
| Quantum Cyber NV | -- |
| MediciNova, Inc. | 68.22% |
| ADMA Biologics, Inc. | 69.31% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -353.6% |
| Return on Assets | -177.3% |
| Return on Invested Capital | -283.3% |
| Profit Margin (Quarterly) | -222.8% |
| Operating Margin (Quarterly) | -220.8% |
| Return on Net Operating Assets | -363.0% |